Press release
12/06/2023
IKI and THERADIAL: towards the launch of an innovative home nutrition monitoring system for patients with chronic renal failure.
Théradial is convinced that IKI offers a medical innovation in line with its development strategy: providing chronic kidney failure patients with innovative, connected tools to improve their nutritional monitoring at home.
THERADIAL and IKI have identified synergies in their respective fields and are working together to optimize access to the URIKI solution for chronic kidney disease patients in France.
THERADIAL
Théradial, a French company founded in 1998, specializes in the distribution of medical devices, pharmaceutical specialties and oral nutritional supplements, mainly for patients suffering from chronic renal failure.
From dialyzers to the prevention and treatment of vascular access complications, Théradial has diversified over the past 25 years, always with the same ambition: to offer patients innovative, differentiating products. Through the distribution of its medical devices (MD) and pharmaceutical specialties, Théradial regularly enriches its product portfolio with innovative devices and original, relevant therapeutic approaches.
In 2019, Théradial acquired two IT companies: Ema and Sined; leaders in IT solutions for monitoring kidney failure patients in France and Italy. This transaction gave birth to the Théradial group.
Today, the Théradial group is recognized for its dynamism and attentiveness to market needs and developments, and is driven by its mission: “Committed to care”, which is rooted in these 4 values: innovation, perseverance, attentiveness and conviviality.
IKI
IKI has developed a home health laboratory, called URIKI, for personalized medical monitoring through simple, portable and accurate urinalysis. Among other things, it enables the monitoring of lifestyle-related chronic illnesses such as chronic kidney disease and cardiovascular disease. To achieve this, it combines a connected urine analyzer, personalized monitoring and patient engagement tools. URIKI’s solution is positioned as a therapeutic patient education tool to optimize nutritional monitoring, in association with the medical team, thanks to objective data: urinary analysis. Urinalysis provides a wealth of information on both the patient’s metabolism and lifestyle.
URIKI is CE-marked (Medical Device for In Vitro Diagnosis: DM-DIV) and protected by patents.
What is Chronic Kidney Disease?
The kidney is a vital organ, responsible for eliminating metabolic waste. Chronic kidney disease (CKD) is an impairment of kidney function that can lead to an accumulation of these wastes in the body. The level of kidney activity is quantified in different stages, from 1 (the kidneys are functioning properly) to 5 (the kidneys are practically non-functioning). At stage 5, replacement therapy (dialysis) or replacement (kidney transplantation) is required. Before this stage, treatments and dietary hygiene rules are implemented to slow the progression of chronic kidney disease.
In chronic renal failure, particularly in stages 3 to 5, nutrition is one of the main levers for slowing down the deterioration of renal function. It is possible to delay the onset of dialysis through nutritional management that limits certain intakes, such as protein and sodium. However, it is sometimes difficult to identify the dietary habits at the root of excessive intake. That’s why the URIKI solution combines a biological analysis at the patient’s home with a food diary to personalize and optimize the patient’s nutritional monitoring in conjunction with his or her medical team.
Conclusion
As a result, THERADIAL and IKI wish to work together to enable French patients suffering from chronic kidney disease to benefit from this innovation in order to improve their nutritional follow-up at home.